Clinical Research in Southampton
Southampton Children's Hospital

A A A Text only | Accessibility | Privacy and cookies

Home
About the Trust
Our services
Patients and visitors
Our hospitals
Education
Research
Working here
Contact us

Browse site A to Z

A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

Search results

Go To Simple Search

Search Type: Criteria:

You could also try: procedure (650), etiquette (1), practice (609)

Atezolizumab1680mg

Description: Chemotherapy Protocol LUNG CANCER Atezolizumab (1680mg 28 days) Regimen • Lung – Atezolizumab Indication • Atezolizumab is indicated for treating previously platinum-treated locally
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lung-cancer-non-small-cellNSCLC/Atezolizumab1680mg.pdf

Nivolumab 240mg (NSCLC)

Description: Chemotherapy Protocol LUNG CANCER – NON-SMALL CELL (NSCLC) Nivolumab (240mg-14 days) Regimen • NSCLC – Nivolumab (240mg-14days) Indication • Nivolumab monotherapy is
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lung-cancer-non-small-cellNSCLC/Nivolumab-240mg.pdf

Atezolizumab(1680-28days)

Description: Chemotherapy Protocol GENITOURINARY CANCER Atezolizumab (1680mg-28 days) Regimen • Urothelial– Atezolizumab (1680mg-28 days) Indication • This protocol was developed in response
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Bladdercancer/Atezolizumab1680-28days.pdf

Everolimus-Lenvatinib

Description: Chemotherapy Protocol RENAL CELL EVEROLIMUS and LENVATINIB Regimen • Renal Cell – Everolimus-Lenvatinib Indication • Confirmed histological diagnosis of inoperable locally advanced or
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Renal-cell/Everolimus-Lenvatinib.pdf

Nivolumab 480mg (renal)

Description: Chemotherapy Protocol RENAL CELL CANCER Nivolumab (480mg-28 days) Regimen • Renal Cell – Nivolumab (480mg-28 days) Indication • Nivolumab is recommended, within
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Renal-cell/Nivolumab-480mg.pdf

Nivolumab 240mg (renal)

Description: Chemotherapy Protocol RENAL CELL CANCER Nivolumab (240mg-14 days) Regimen • Renal Cell – Nivolumab (240mg-14 days) Indication • Nivolumab is recommended, within
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Renal-cell/Nivolumab-240mg.pdf

Nivolumab 240mg (lymphoma)

Description: Chemotherapy Protocol LYMPHOMA Nivolumab (240mg-14 days) Regimen • Lymphoma – Nivolumab (240mg-14 days) Indication • Nivolumab is recommended as an option for
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/Nivolumab-240mg.pdf

InP-BEAM

Description: Chemotherapy Protocol LYMPHOMA CARMUSTINE-CYTARABINE-ETOPOSIDE (split)-MELPHALAN (BEAM) Inpatient Regimen Regimen Lymphoma – InP-BEAM (split)-Carmustine-Cytarabine-Etoposide-Melphalan Indication
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/InP-BEAM.pdf

DRC-Cyclophosphamide-Dexamethasone-Rituximab

Description: Chemotherapy Protocol LYMPHOMA CYCLOPHOSPHAMIDE - DEXAMETHASONE – RITUXIMAB (DRC) Regimen • Lymphoma – DRC – Cyclophosphamide – Dexamethasone - Rituximab Indication • Lymphophlasmacytic lymphoma / Waldenstrom’s macroglobinaemia Toxicity Drug
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/DRC-Cyclophosphamide-Dexamethasone-Rituximab.pdf

ChlVPP-EVA-Chlorambucil-Doxorubicin-Etoposide-Prednisolone-Procarbazine-Vinblastine-Vincristine

Description: Chemotherapy Protocol LYMPHOMA CHLORAMBUCIL-DOXORUBICIN-ETOPOSIDE-PREDNISOLONE-PROCARBAZINEVINBLASTINE-VINCRISTINE (ChlVPP-EVA) Regimen • Lymphoma – ChlVPP-EVA-Chlorambucil-Doxorubicin-Etoposide-PrednisoloneProcarbazine-Vinblastine-Vincristine
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/ChlVPP-EVA-Chlorambucil-Doxorubicin-Etoposide-Prednisolone-Procarbazine-Vinblastine-Vincristine.pdf

301 to 310 of 698

Previous … 29 30 31 32 33 … Next